412 related articles for article (PubMed ID: 23782935)
1. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.
Quintás-Cardama A; Abdel-Wahab O; Manshouri T; Kilpivaara O; Cortes J; Roupie AL; Zhang SJ; Harris D; Estrov Z; Kantarjian H; Levine RL; Verstovsek S
Blood; 2013 Aug; 122(6):893-901. PubMed ID: 23782935
[TBL] [Abstract][Full Text] [Related]
2. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
Quintás-Cardama A; Kantarjian H; Manshouri T; Luthra R; Estrov Z; Pierce S; Richie MA; Borthakur G; Konopleva M; Cortes J; Verstovsek S
J Clin Oncol; 2009 Nov; 27(32):5418-24. PubMed ID: 19826111
[TBL] [Abstract][Full Text] [Related]
3. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.
Kiladjian JJ; Cassinat B; Chevret S; Turlure P; Cambier N; Roussel M; Bellucci S; Grandchamp B; Chomienne C; Fenaux P
Blood; 2008 Oct; 112(8):3065-72. PubMed ID: 18650451
[TBL] [Abstract][Full Text] [Related]
4. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
[TBL] [Abstract][Full Text] [Related]
5. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
[TBL] [Abstract][Full Text] [Related]
6. [Efficiency of interferon therapy in patients with essential thrombocythemia or polycythemia vera].
Sokolova MA; Turkina AG; Melikian AL; Sudarikov AB; Treglazova SA; Shukhov OA; Gemdzhian EG; Abdullaev AО; Kovrigina AM; Misyurin AV; Pliskunova YV; Ivanova VL; Moiseeva TN
Ter Arkh; 2016; 88(12):69-77. PubMed ID: 28139563
[TBL] [Abstract][Full Text] [Related]
7. Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms.
Pedersen RK; Andersen M; Knudsen TA; Sajid Z; Gudmand-Hoeyer J; Dam MJB; Skov V; Kjaer L; Ellervik C; Larsen TS; Hansen D; Pallisgaard N; Hasselbalch HC; Ottesen JT
Cancer Med; 2020 Mar; 9(6):2039-2051. PubMed ID: 31991066
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
Yacoub A; Mascarenhas J; Kosiorek H; Prchal JT; Berenzon D; Baer MR; Ritchie E; Silver RT; Kessler C; Winton E; Finazzi MC; Rambaldi A; Vannucchi AM; Leibowitz D; Rondelli D; Arcasoy MO; Catchatourian R; Vadakara J; Rosti V; Hexner E; Kremyanskaya M; Sandy L; Tripodi J; Najfeld V; Farnoud N; Papaemmanuil E; Salama M; Singer-Weinberg R; Rampal R; Goldberg JD; Barbui T; Mesa R; Dueck AC; Hoffman R
Blood; 2019 Oct; 134(18):1498-1509. PubMed ID: 31515250
[TBL] [Abstract][Full Text] [Related]
9. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.
Stauffer Larsen T; Iversen KF; Hansen E; Mathiasen AB; Marcher C; Frederiksen M; Larsen H; Helleberg I; Riley CH; Bjerrum OW; Rønnov-Jessen D; Møller MB; de Stricker K; Vestergaard H; Hasselbalch HC
Leuk Res; 2013 Sep; 37(9):1041-5. PubMed ID: 23827351
[TBL] [Abstract][Full Text] [Related]
10. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.
Tefferi A; Pardanani A; Lim KH; Abdel-Wahab O; Lasho TL; Patel J; Gangat N; Finke CM; Schwager S; Mullally A; Li CY; Hanson CA; Mesa R; Bernard O; Delhommeau F; Vainchenker W; Gilliland DG; Levine RL
Leukemia; 2009 May; 23(5):905-11. PubMed ID: 19262601
[TBL] [Abstract][Full Text] [Related]
11. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.
Kiladjian JJ; Cassinat B; Turlure P; Cambier N; Roussel M; Bellucci S; Menot ML; Massonnet G; Dutel JL; Ghomari K; Rousselot P; Grange MJ; Chait Y; Vainchenker W; Parquet N; Abdelkader-Aljassem L; Bernard JF; Rain JD; Chevret S; Chomienne C; Fenaux P
Blood; 2006 Sep; 108(6):2037-40. PubMed ID: 16709929
[TBL] [Abstract][Full Text] [Related]
12. Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis.
Zhang ZR; Duan YC
Asian Pac J Cancer Prev; 2014; 15(4):1681-4. PubMed ID: 24641389
[TBL] [Abstract][Full Text] [Related]
13. Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy.
O'Neill C; Siddiqi I; Brynes RK; Vergara-Lluri M; Moschiano E; O'Connell C
Ann Hematol; 2016 Apr; 95(5):733-8. PubMed ID: 26961933
[TBL] [Abstract][Full Text] [Related]
14. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia.
Samuelsson J; Mutschler M; Birgegård G; Gram-Hansen P; Björkholm M; Pahl HL
Haematologica; 2006 Sep; 91(9):1281-2. PubMed ID: 16956836
[TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.
Verger E; Cassinat B; Chauveau A; Dosquet C; Giraudier S; Schlageter MH; Ianotto JC; Yassin MA; Al-Dewik N; Carillo S; Legouffe E; Ugo V; Chomienne C; Kiladjian JJ
Blood; 2015 Dec; 126(24):2585-91. PubMed ID: 26486786
[TBL] [Abstract][Full Text] [Related]
16. Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Dam MJB; Pedersen RK; Knudsen TA; Andersen M; Skov V; Kjaer L; Hasselbalch HC; Ottesen JT
Eur J Haematol; 2021 Dec; 107(6):624-633. PubMed ID: 34411333
[TBL] [Abstract][Full Text] [Related]
17. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y
Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989
[TBL] [Abstract][Full Text] [Related]
18. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells.
Lu M; Wang X; Li Y; Tripodi J; Mosoyan G; Mascarenhas J; Kremyanskaya M; Najfeld V; Hoffman R
Blood; 2012 Oct; 120(15):3098-105. PubMed ID: 22872685
[TBL] [Abstract][Full Text] [Related]
19. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.
Senín A; Fernández-Rodríguez C; Bellosillo B; Camacho L; Longarón R; Angona A; Besses C; Álvarez-Larrán A
Ann Hematol; 2018 Mar; 97(3):443-451. PubMed ID: 29181548
[TBL] [Abstract][Full Text] [Related]
20. [Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis].
Bai J; Xue YP; Zhang L; Li CH; Fan DM; Li B; Xu SC; Li DP; Sun XJ; Jiang B; Yang RC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):444-9. PubMed ID: 21518505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
